Skip to main content

Porvair, Suzhou Tianlong Biotechnology Partner on Personalized Medicine Tech

NEW YORK (GenomeWeb) – Porvair Sciences announced today that it has partnered with Suzhou Tianlong Biotechnology to develop epigenetic technologies for precision medicine.

The effort is part of the Innovate UK/Jiangsu Industrial Challenge Program, which was launched to promote economic development in the UK and the Jiangsu province in China. According to Porvair, the partners will integrate its Chromatrap solid-state chromatin immunoprecipitation platform with Tianlong's automated robotics and multiplex PCR kits in order to develop epigenetic assays for patient stratification and personalized treatment, with an initial focus on breast and ovarian cancer.

Collaborators at Swansea University and Xi'an Jiaotong University will assist the companies by providing expertise and guidance in cancer research and drug development.

Financial terms of the partnership were not disclosed.

"Combining Chromatrap with Tianlong's expertise in diagnostic multiplex arrays, we will provide a streamlined workflow across both research and clinical applications," Amy Beynon, technical and business development manager at Provair, said in a statement. "The ultimate collaborative goal is to provide innovative tools that improve diagnostic options for patients and informed novel stratified therapeutics."